Articles tagged with Pharmacology
Researchers are using 3D cardiac constructs to model cardiovascular diseases and test new drugs. These constructs can capture the complexity of human cardiac tissue, including its electrical activity, metabolism, and cellular communication. The field is advancing with biomaterials, AI-assisted screening, and improved standardization.
Researchers developed a new eye drop treatment that significantly reduced dry eye disease characteristics, such as inflammation and loss of goblet cells. The treatment uses a rexinoid compound that boosts the protective role of resident macrophages, promoting debris-clearing and immune balance.
The new edition of the Wiley Registry of Mass Spectral Data 2026 expands compound coverage to over 915,500 reference spectra, strengthening a foundational layer of scientific data and research intelligence. This expansion enables researchers to identify unknown chemical compounds and materials faster with confidence.
A study by EHU researchers found that exercising outdoors can help combat vitamin D deficiency and strengthen the immune system. The study suggests that taking vitamin D supplements has no direct effect on physical performance, contrary to popular belief.
A new study by the University of Southampton has found that reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections. The study followed hundreds of patients for a year and discovered that those who tested reusable catheters used 35 per cent fewer antibiotics.
A major new study has found that severe asthma patients are often battling other health conditions, with nearly all suffering from at least one major issue. The study identified three distinct profiles linked to how well asthma is controlled and the treatments needed, offering potential breakthroughs for improving care.
Researchers at Mizzou's Molecular Imaging and Theranostics Center developed an automated approach to producing the prostate cancer treatment. The new method produces CTT1403 in just 38 minutes, compared to six hours with traditional methods, using a commercially available automated synthesis system.
The Alliance A082402 study evaluates the effectiveness of involved-station I²-PORT in reducing NSCLC recurrence without long-term side effects. Participants will undergo randomized treatment with or without targeted radiation therapy after surgery.
A new statistical approach used in Alzheimer's disease trials may exaggerate the link between amyloid reduction and cognitive benefits of new drugs. Researchers found that combining large groups of patients can hide variability and make it appear as if reducing amyloid is more predictive of cognitive benefit than it actually is.
Researchers developed a new scale to estimate the risk of using medicines while driving, combining factors such as adverse effects and dosage. The FMB scale offers greater resolution than existing systems like DRUID, allowing for more precise identification of medicines with similar profiles.
Researchers developed genESOM, a generative AI that can expand dataset volume and simulate larger animal numbers while maintaining reliability. This allows for 30-50% reduction in animal experiments without compromising results.
Recent advances in medications, devices, and care pathways are redefining heart failure (HF) treatment. Emerging therapies beyond traditional EF silos have demonstrated broad efficacy across LVEF categories.
Researchers at Leibniz Institute for Food Systems Biology found that bitter-tasting herbal extracts stimulate proton secretion in human gastric cells, with polyphenol-rich extracts showing the strongest effects. The study identified three human bitter taste receptor subtypes as key mediators of this response.
A new study from the University of Virginia finds that next-generation GLP-1 drugs can alter brain circuits controlling motivation and reward. The research shows that these drugs not only suppress appetite but also influence how the brain values food, helping explain their effectiveness and side effects.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
The article systematically summarizes forty years of discoveries in the TLR field, revealing multilayered regulatory mechanisms governing TLR signaling. Aberrant TLR signaling is closely linked to multiple human diseases, including infectious diseases, autoimmune conditions, and cancer.
Researchers engineer bacterial vesicles into multifunctional tools that can kill pathogens, boost vaccines, and deliver targeted therapies. Engineered BEVs address key limitations of existing therapies, including improving vaccine responses and antibiotic delivery.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
Two UVA scientists, Edward H. Egelman and James N. Galloway, were elected to the prestigious American Academy of Arts & Sciences for their outstanding contributions to biochemistry, environmental sciences, and research. The recognition acknowledges their collective breadth and depth of excellence in advancing public good.
Researchers aim to develop novel quantum algorithms for molecular simulation, targeting computational bottlenecks in drug discovery. The collaboration combines expertise in quantum chemistry and sampling techniques with quantum computing capabilities.
A research consortium has developed mini-antibodies that can reactivate mutated p53, a key tumor suppressor protein. These DARPins bind selectively to p53 mutants, restoring stability and functionality, making them potentially useful against various types of tumors.
Chronic liver disease in the US costs $41.57 billion, with prescription medication expenditures accounting for nearly half of all-cause healthcare expenditures. Poor adherence to antiviral medications is a key factor in preventing disease progression and treatment, with high out-of-pocket costs increasing non-adherence risk.
EGFR-TKIs have significantly improved OS and quality of life for EGFR-mutant NSCLC patients. However, ongoing research is needed to refine therapies for precise individualized treatment, addressing resistance mechanisms and optimal combination strategies.
A $456,000 grant from Critical Path Institute will support the development of a brain-penetrant therapy for glycosphingolipid storage disorders. The therapy aims to address neurological symptoms in patients with current limited treatment options.
Researchers at the University of East Anglia have discovered that light can be programmed using its natural geometry, allowing for the creation of structured light with unique properties. This breakthrough has far-reaching implications for fields such as medicine, data transmission, and quantum technologies.
Researchers at the University of British Columbia have developed a new method to target intrinsically disordered proteins, which are difficult to treat with medication. The approach has shown promise in slowing prostate cancer growth and could lead to new treatments for various diseases.
A new study found that nearly 1,200 TBI respondents used psychedelics to treat or manage physical health conditions, with 208 participants using them to manage brain injury-related symptoms. Researchers reported a 90% self-reported symptom improvement rate.
Researchers identified a new compound, Apilimod, that prevents hepatitis E virus infection by blocking a key cellular process, PIKfyve. This approach may offer a more effective treatment with lower risk of resistance development.
Researchers have overcome epigenetic silencing to create genetically engineered chickens that can hatch with useful medical proteins. This breakthrough could lead to the development of stable lines of birds that lay eggs containing beneficial proteins.
A study found that HAART led to a resurgence of syphilis in the US, with increases concentrated among men. The availability of HIV treatments improved survival but also changed sexual behavior and public health effects.
Researchers discovered a biomarker that can predict disease progression and mortality in patients with severe heart failure. Mid-regional pro-adrenomedullin (MR-proADM) levels are associated with greater disease severity, mortality, and heart failure events.
The 12th ARDD meeting emphasized the importance of reversing biological age and identifying molecular mechanisms that can be targeted to modify them. Researchers presented new biomarkers and AI-designed proteins to develop novel therapeutics, with a focus on integrated, multi-targeted therapeutic strategies.
The Alliance for Clinical Trials in Oncology has several active trials specifically designed to help people with head and neck cancers. Trials include testing high-dose prophylactic gabapentin to prevent opioid use during treatment, as well as immunotherapy with nivolumab and cabozantinib for mucosal melanoma and nasopharyngeal carcino...
A new study by University College London found that gabapentinoids, prescribed for chronic pain, double the risk of hospitalization for drug poisoning when combined with benzodiazepines or opioids. The risk persists even after starting gabapentinoid treatment, suggesting they may not be an effective solution to reduce poisoning risks.
Researchers developed an ovarian follicle-based angiogenesis microphysiological system that forms complex 3D vascular networks without exogenous VEGF. The platform enables direct visualization and quantitative analysis of vascular remodeling, allowing for the rapid identification of anti-angiogenic compounds with meaningful in vivo act...
A study by Ebenbuild confirms strong predictive performance of patient-specific lung digital twins, validated against clinical imaging data. The model's accuracy was demonstrated through a correlation coefficient of 0.95 with experimental data, enabling locally resolved predictions of aerosol deposition at the individual patient level.
A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.
Researchers found that squalene-based adjuvants activate distinct pathways for vaccine protection and reactogenicity, including the role of IL-1β in enhancing efficacy and IL-1α in triggering local swelling. The study's findings could lead to safer vaccine design by targeting specific immune mechanisms.
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
Scientists at the University of Kent have found that madecassic acid inhibits the ability of antibiotic-resistant E. coli to grow, suggesting it could serve as an alternative antimicrobial. The study shows three modified variants of the compound effectively inhibited cytochrome bd and shut down bacterial growth.
Scientists at NTU Singapore found that glycerol-3-phosphate acyltransferase (GPAT) amplifies α-synuclein toxicity by altering fat metabolism in brain cells. Targeting GPAT activity may offer a new strategy for treating Parkinson's disease.
Researchers discovered that neuronal nitric oxide synthase drives neuroblastoma through the mTOR signaling cascade. Treating cancer cells with a selective inhibitor called BA-101 collapsed tumor growth in mice with striking force, and silencing the nNOS gene also led to significant results.
A hormone called FGF21 reverses obesity in mice by signaling to the hindbrain, a region targeted by GLP-1 drugs. This finding provides insight into the naturally occurring hormone's benefits for weight loss and MASH treatment.
In this randomized clinical trial, mirtazapine effectively reduced methamphetamine use in adults with methamphetamine use disorder. The study's findings have important implications for the treatment of this condition, which currently lacks approved pharmacotherapies.
Researchers discovered that even tiny amounts of PFDA cause visible facial changes and increase risk by 10% at low exposure levels. PFDA blocks key enzyme CYP26A1, disrupting retinoic acid metabolism and leading to abnormal facial development.
A study reveals dermcidin, a human body natural molecule, exhibits antiviral activity against the influenza virus. Higher baseline levels of dermcidin in individuals who don't develop flu-like symptoms may be associated with lower susceptibility to infection.
Scientists have discovered genetic pathways and compounds that protect cone photoreceptors, crucial for central vision, from degeneration associated with age-related macular degeneration. The study used human retinal organoids and identified two kinase inhibitors as key protective mechanisms.
A new approach allows oral delivery of drugs previously requiring injection by piggybacking on natural fat absorption pathways. The medication, GlyphAllo, bypasses the liver's security checkpoint and is absorbed through the gut's lymphatic system, allowing it to enter the bloodstream directly.
A team of researchers has developed a novel 3D atlas technology, enabling comprehensive understanding of cell distribution across entire organs or the whole organism. This innovation combines with existing gene expression data to advance disease understanding and create new indicators.
Researchers have discovered how a light-switchable beta blocker interacts with its biological receptor, allowing for targeted treatment of high blood pressure. The new compound's shape changes in response to light, reducing its potency and minimizing side effects.
Researchers have developed a low-cost fake drug detector that uses an infrared sensor to track pill dissolution rates. The device can identify legitimate medications from counterfeit ones with high accuracy, making it a valuable tool in the fight against global health threats.
Researchers engineered Escherichia coli Nissle 1917 bacteria to produce anticancer agent Romidepsin, which was released from the bacteria and effectively targeted cancer cells in mouse models. The study establishes a solid foundation for bacteria-assisted tumor-targeted therapy, paving the way for future advancements in cancer treatment.
Dr. Gobbi challenges the global drug-development system, stating that promising treatments for mental illness are failing to reach patients due to venture capital and profit motives. Her research focuses on cannabis, melatonin, and psychedelics, with a goal of improving public-health decisions and treatment outcomes.
Scientists have discovered that mosquitoes use a specific sensory receptor to detect and avoid borneol, an organic compound found in plant-based mosquito repellents. This finding has the potential to lead to the development of more effective and longer-lasting repellents.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
Researchers at the University of Edinburgh have developed a method to transform post-consumer plastic into L-DOPA, a frontline medication for Parkinson's disease. The process harnesses the power of bacteria to break down PET waste and produce L-DOPA, providing a sustainable solution to the production of pharmaceuticals.
Scientists identify Roseburia genus bacteria in human intestine associated with increased muscle mass and strength. The study suggests that the bacteria could be used as a probiotic to help preserve muscle strength during aging.
Researchers developed GluBs to target ASCT2 in aggressive cancers, bypassing the LAT1 route. The agents showed efficacy in limiting tumor growth and demonstrating potential to treat cancers with limited LAT1 expression.